The Enzyme That Determines Your Trip
Cytochrome P450 2D6 (CYP2D6) is a liver enzyme responsible for metabolizing approximately 25% of all commonly used drugs — including DXM. Its role in DXM pharmacology is critical because it converts DXM into its primary active metabolite, dextrorphan (DXO), which is a more potent NMDA antagonist.
Metabolizer Phenotypes
Extensive Metabolizers (EM)
Most people — roughly 77-92% depending on ethnicity — are extensive metabolizers with two functional CYP2D6 gene copies. In EMs, DXM is metabolized to DXO at a normal rate. The ratio of DXM:DXO at any given time reflects this steady conversion. This is the “expected” pharmacological profile on which standard dose ranges are based.
Poor Metabolizers (PM)
Approximately 5-10% of Caucasians, 1-3% of Asians, and 3-8% of Africans are CYP2D6 poor metabolizers, having two non-functional gene copies. In PMs, DXM is barely converted to DXO. This has profound consequences:
- DXM accumulates to much higher plasma levels than expected
- The experience is dominated by DXM (more sigma-1 activity) rather than DXO (NMDA antagonism)
- Effects may be qualitatively different from EM experiences
- Standard recreational doses can be equivalent to significantly higher doses in EMs
- Duration is substantially extended
If you are a CYP2D6 PM, starting doses should be significantly lower than standard recommendations.
Ultrarapid Metabolizers (UM)
Some people have multiple functional CYP2D6 gene copies (gene duplication), making them ultrarapid metabolizers. In UMs, DXM is converted to DXO so rapidly that DXM barely accumulates. Effects may be weaker or shorter-lived. Some UMs report minimal effects at doses others find significant.
Intermediate Metabolizers (IM)
A range between EM and PM, with one functional and one non-functional allele. Effects fall between the two extremes.
CYP2D6 Inhibitors
Even extensive metabolizers can effectively become poor metabolizers temporarily when taking CYP2D6 inhibitors. Common inhibitors include:
- Fluoxetine (Prozac) — potent inhibitor with very long half-life (days to weeks)
- Paroxetine (Paxil) — very potent inhibitor
- Bupropion (Wellbutrin) — moderate to potent inhibitor
- Duloxetine (Cymbalta) — moderate inhibitor
- Diphenhydramine (Benadryl) — moderate inhibitor
- Cinacalcet, haloperidol, terbinafine — potent inhibitors
Taking DXM while on a CYP2D6 inhibitor can dramatically increase DXM blood levels and push the effective dose into a higher plateau than intended. This is an underappreciated source of unexpected overdose.
Should You Test Your CYP2D6 Status?
Consumer pharmacogenomic tests (like 23andMe or dedicated pharmacogenomics services) can report your CYP2D6 metabolizer status. If you have access to this testing, it provides genuinely useful harm reduction information. If you suspect you may be a poor metabolizer (unusual sensitivity to many medications, particularly codeine and other drugs metabolized by 2D6), start at significantly lower doses.